Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1771 • ACR Convergence 2025
Interferon- α, Anti-Interferon-Alpha Antibodies and Disease Activity in Systemic Lupus Erythematosus
Gollakota Nandita¹, Kambhampati Sreelekha², Kaushik Puranam³, Phani Kumar D⁴, Meghna Gavali⁵ and Liza rajasekhar⁶, ¹NIMS, Hyderabad, Hyderabad, Telangana, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³Nizams Institute Of Medical Sciences , Hyderabad, hyderabad, Telangana, India, ⁴NIMS, Hyderabad, Telangana, India, ⁵nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ⁶Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease, partly driven by Interferon-alpha (IFN-α). Studies suggest that anti-IFN-α antibodies (AIAA) may neutralize IFN-α, potentially…
Abstract Number: 1700 • ACR Convergence 2025
Altered Gene Expression In Male SLE Is Mapped To a Male-Specific Y Chromosome Locus Associated with Microdeletions
Mikhail Olferiev¹, Kyriakos Kirou¹, Emily Wu², Dina Greenman¹ and Mary Crow³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Union City, NJ, ³Hospital for Special Surgery, New York
Background/Purpose: SLE occurs more frequently in females than males, with relative prevalence 9-10:1. While the impact of hormones on immune function may contribute to the…
Abstract Number: 1575 • ACR Convergence 2025
Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
Kevin Chevalier¹, Brigitte Bader-Meunier², Isabelle Kone-Paut³, Benjamin Torreau⁴, Marc Michel⁵, Bertrand Godeau⁵, Christian AGARD⁶, Thomas Papo⁷, Karim Sacré⁸, Raphaele Seror⁹, Xavier Mariette¹⁰, Cacoub Patrice¹¹, Ygal Benhamou¹², Mathilde Leclercq¹³, Cécile goujard¹⁴, Olivier Lambotte³, Bernard Bonnotte¹⁵, Maxime Samson¹⁶, Félix Ackermann¹⁷, Jean Schmidt¹⁸, Pierre Duhaut¹⁸, Jean-Emmanuel Kahn¹⁹, Thomas Hanslik¹⁹, Nathalie Costedoat-Chalumeau²⁰, Benjamin Terrier²⁰, Alexis REGENT²¹, bertrand Dunogue²², Pascal Cohen²³, Véronique Le Guern²⁰, Eric HACHULLA²⁴, Luc Mouthon²² and Benjamin Chaigne²², ¹Université Paris Cité, Montrouge, France, ²Necker hospital, Paris, France, ³Bicêtre hospital, Kremlin Bicêtre, France, ⁴Internal Medicine and Immunology, CHU Tours, Tours, France, ⁵Henri Mondor hospital, Créteil, France, ⁶Internal medicine, Nantes University Hospital, Nantes, France, ⁷Bichat hospital, Paris, France, ⁸Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹⁰Université Paris-Saclay, Le Kremlin Bicetre, France, ¹¹Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹²Internal Medicine, CHU Rouen, Rouen, France, ¹³Rouen hospital, Rouen, France, ¹⁴Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹⁵Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France, ¹⁶CHU Dijon Bourgogne, Dijon, France, ¹⁷Foch hospital, Suresnes, France, ¹⁸Amiens hospital, Amiens, France, ¹⁹Ambroise Paré hospital, Boulogne, France, ²⁰Cochin hospital, Paris, France, ²¹Hopital Cochin, Paris, France, ²²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France
Background/Purpose: Mixed connective tissue disease (MCTD) is an entity defined by clinical features of differentiated connective tissue diseases (dCTD), such as systemic lupus erythematosus (SLE),…
Abstract Number: 1535 • ACR Convergence 2025
INB-619 – A Novel Gamma-Delta (γδ) T cell Engager to Target B cells in Autoimmune Diseases
Lei Ding, Yanjie Li, Mariska ter Haak, Sadhak Sengupta, Kate Rochlin and Lawrence Lamb, IN⁸bio, Inc., New York, NY
Background/Purpose: T cell engagers (TCEs) redirect T cells to bind target cells by linking T cells with target-associated antigens expressed on cells responsible for disease…
Abstract Number: 1516 • ACR Convergence 2025
The Benefits of SGLT2i on GFR Slope and Proteinuria in SLE Depend on Subgroups of Diabetes Mellitus and Baseline eGFR
Jennifer Lee¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) affects over 50% of SLE patients. Twenty percent of LN patients develop end-stage renal disease (ESRD) within 10 years. The 2021…
Abstract Number: 1492 • ACR Convergence 2025
Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus
Katherine Moseley¹, Dulaney Wilson², Emily Vara¹ and Diane Kamen³, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Medical University of South Carolina, Johns Island, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder that is nine times more prevalent in women. Patients with SLE are at an…
Abstract Number: 1474 • ACR Convergence 2025
Rethinking Heart Risk Prediction for Lupus Patients
Aretha On¹, Xiwei Yang¹, Shae Chambers², Hammad Ali³, Touraj Khosravi-Hafshejani³, Lais Lopes Almeida Gomes², Rui Feng⁴, Kevin Jon Williams⁵ and Victoria Werth⁶, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, U.S./Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, U.S., Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, ⁵Department of Cardiovascular Sciences, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA, Philadelphia, PA, ⁶University of Pennsylvania, Wynnewood, PA
Background/Purpose: Patients with lupus erythematosus (LE) are at an increased risk of clinical events from atherosclerotic cardiovascular disease (ASCVD), yet the accuracy of risk estimation…
Abstract Number: 1289 • ACR Convergence 2025
Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Jida Jaffan¹, Tala El Tal², Lawrence Ng³, Asha Jeyanathan⁴, Hunter Hogarth⁵, Adrienne Davis⁴, Linda Hiraki⁵, Deborah Levy⁵, Zahi Touma⁶, Natoshia Cunningham⁷, Ashley Danguecan⁸ and Andrea Knight⁸, ¹The Hospital for Sick Children/ University of Toronto, Toronto, ON, Canada, ²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Michigan State University, Grand Rapids, MI, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Pain is a common symptom in childhood-onset systemic lupus erythematosus (cSLE) which impacts health-related quality of life. Its relationship to disease measures over time…
Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Valerie Devauchelle¹, Swati Ghanshani², CAROLE SIPS³, Rainer Hillenbrand³, Carol Lau⁴, Wolfgang Hueber⁵, Claire Bonal³ and Stephen Oliver⁶, ¹UBO, Brest, France, ²Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ³Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…
Abstract Number: 1018 • ACR Convergence 2025
Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
José Gomez-Puerta¹, Cristian Tebe², Maria Grau³, Beatriz Frade Sosa⁴, Juan Camilo Sarmiento-Monroy⁵, Cristina Carbonell-Abella⁶, Daniel Martinez-Laguna⁷, Patricia Corzo⁸, Raimon Sanmartí⁹ and J. Antonio Aviña-Zubieta¹⁰, ¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²Instituto de Investigación Germans Trias i Pujol, Badalona, Spain, ³University of Barcelona, Barcelona, Spain, ⁴Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁵Hospital Clínic Barcelona, Barcelona, Spain, ⁶Medicina Familiar y Comunitaria, Centro de Salud Vía Roma, Barcelona, Spain, ⁷Grup de recerca en malalties prevalents de l'Aparell locomotor en Atenció Primaria (GREMPAL), ICS, Barcelona, Spain, ⁸Rheumatology Department, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁰University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: The differences in lupus-related mortality reported in population studies are partly explained by racial disparities and access to healthcare. However, population-based data from universal…
Abstract Number: 0936 • ACR Convergence 2025
Ultrasound-Mediated Blood–Brain Barrier Permeabilization Enables Targeted Drug Delivery in a Murine Model of Neuropsychiatric SLE
Doaa Tehawey¹, Roni Gattegno², Baruh Polis¹, Mike Bismuth², Melodie Zaknoun¹, Tali Ilovitsh² and Chaim Putterman³, ¹Azrieli Faculty of Medicine, Safed, Israel, ²Tel Aviv University, Tel-Aviv, Israel, ³Albert Einstein College of Medicine, Safed, Israel
Background/Purpose: Neuropsychiatric SLE (NPSLE) is a severe complication of SLE, characterized by CNS involvement leading to cognitive, behavioral, and neurological deficits. While monoclonal antibodies may…
Abstract Number: 0666 • ACR Convergence 2025
Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
Sarah Crisci, New York University, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with heterogeneous symptoms, complicating diagnosis and treatment. Historically, treatment included broad immunosuppressants, but real-world data…
Abstract Number: 0641 • ACR Convergence 2025
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Melanie Hagen¹, Andreas Wirsching¹, Fabian Müller², Soraya Kharboutli³, Christina Bergmann¹, Sebastian Böltz¹, Jule Taubmann⁴, Carlo Tur¹, Laura Bucci¹, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Louis Schuster⁴, Koray Tascilar⁴, Silvia Spoerl³, Ingrid Vasova³, Panagiotis Garantziotis¹, Daniel Aletaha⁵, Hans-Peter Kiener⁶, gerlando Natalello⁷, Franco Locatelli⁸, Maria Antonietta D'Agostino⁹, Aline Bozec¹, Linda Hanssens¹⁰, Dirk De Vries¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical University Vienna, Wien, Austria, ⁶Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁷Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁹Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁰Miltenyi Biomedicine, Bergisch Gladbach, Bergisch Gladbach, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Engineered T cells expressing a chimeric antigen receptor (CAR) binding CD19 are powerful tools to deplete B-cells, representing an attractive therapy for severe autoimmune…
Abstract Number: 0621 • ACR Convergence 2025
Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
Luis Javier Cajas Santana¹, Sebastián Molina-Ríos¹, Lucia Hernández², Romina Nieto³, Gricel Maita Romero⁴, Nidia Noemí Merás⁵, Veronica Gabriela Savio⁶, Veronica Saurit⁷, Valeria Arturi⁸, Boris Kisluk⁹, Inés Verónica Bellomio¹⁰, Mario Eduardo Kerzberg¹¹, Nicolas Perez¹², Cecilia Pisoni¹³, Vicente Juarez¹⁴, Joaquín Martinez Serventi¹⁵, Nélzio Silva¹⁶, ODIRLEI MONTICIELO¹⁷, Mariana Souza Pessoa de Luna¹⁸, Laíssa Cristina Alves Alvino¹⁹, Eduardo Borba²⁰, Luciana Parente Costa Seguro²⁰, Edgard dos Reis-Neto²¹, Iris Guerra Herrera²², Milena Mimica²³, Gustavo Aroca Martínez²⁴, Valentina Pérez jiménez²⁵, Carlos Alberto Cañas²⁶, Gerardo Quintana-Lopez²⁷, Carlos Toro-Gutierrez²⁸, Rafael Ignacio López Martínez²⁹, MIGUEL SAAVEDRA³⁰, Margarita Portela Hernández³¹, Hilda Fragoso-Loyo³², Luis H Silveira³³, Yelitza Gonzalez Bello³⁴, Carlos Abud-Mendoza³⁵, Jorge Antonio Esquivel Valerio³⁶, Patricia Langjahr³⁷, Astrid Paats³⁸, Claudia S. Mora-Trujillo³⁹, Victor Pimentel-Quiroz⁴⁰, Carlos Bedia⁴¹, Teresandris Polanco Mora⁴², Martin Rebella⁴³, Alvaro Danza⁴⁴, Federico Zazzetti⁴⁵, Ashley Orillion⁴⁶, Guillermo Pons-Estel³ and Graciela Alarcón⁴⁷, ¹Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina;, Córdoba, Argentina, ⁶Universidad Nacional de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ⁷Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁸Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, ⁹Sanatorio Británico, Rosario, Argentina, Rosario, Argentina, ¹⁰Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, ¹¹Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, ¹²Instituto de Investigaciones Médicas Dr. Alfredo Lanari, Buenos Aires, Argentina, ¹³CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, ¹⁴Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁵Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁶Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ¹⁷Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁸Universidad Federal de Pernambuco, Recife, Brazil, Recife, Brazil, ¹⁹Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁰Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²¹Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, ²²Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²³Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²⁴Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ²⁵Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, ²⁶Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁷Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²⁸Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ²⁹Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁰Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, ³¹Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³⁴Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, ³⁵Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, ³⁶Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁷Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, San Lorenzo, Paraguay, ³⁸Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, ³⁹Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ⁴⁰Universidad Científica del Sur, San Isidro, Peru, ⁴¹Hospital Nacional Cayetano Heredia, Universidad Peruana Cayetano Heredia, Lima, Peru, Lima, Peru, ⁴²Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴³Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁴Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁵Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁶Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁷The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystemic autoimmune disease. Pleuropulmonary (PP) manifestations, including pleural effusion (PE), interstitial lung disease (ILD), pulmonary hypertension (PH), shrinking…
Abstract Number: 0606 • ACR Convergence 2025
Increased Recombinant Zoster Vaccination in SLE following Public Reimbursement: Data from Two Prospective SLE Cohorts
Arielle Mendel¹, Nathalie Amiable², Yvan St-Pierre³, Sasha Bernatsky⁴, Ines Colmegna⁵, Michaël Desjardins⁶, Louis-Pierre Grenier⁷, Fares Kalache⁸, Christian Pineau⁹, Chantal Sauvageau¹⁰, Evelyne Vinet⁴ and Paul Fortin¹¹, ¹McGill University Health Centre, Montréal, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Centre Hospitalier de l'Université de Montréal (CHUM)), Montreal, QC, Canada, ⁷Montreal General Hospital, Montréal, QC, Canada, ⁸McGill University Health Center, Montreal, QC, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Institut national de santé publique du Québec, Quebec City, QC, Canada, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Herpes Zoster (shingles) is a common preventable adverse event in SLE. In Quebec, Canada, the Recombinant Zoster Vaccine (RZV) became free of charge for…

« Previous Page
1
…
5
6
7
8
9
…
181
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].